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Abstract
Wolfram syndrome, an autosomal recessive disorder characterized by juvenile-
onset diabetes mellitus and optic atrophy, is caused by mutations in the WFS1
gene. WFS1 encodes an endoplasmic reticulum resident transmembrane pro-
tein. The Wfs1-null mice exhibit progressive insulin deficiency and diabetes.
The aim of this study was to describe the insulin secretion and transcriptome
of pancreatic islets in WFS1-deficient mice. WFS1-deficient (Wfs1KO) mice
had considerably less pancreatic islets than heterozygous (Wfs1HZ) or wild-
type (WT) mice. Wfs1KO pancreatic islets secreted less insulin after incuba-
tion in 2 and 10 mmol/L glucose and with tolbutamide solution compared to
WT and Wfs1HZ islets, but not after stimulation with 20 mmol/L glucose.
Differences in proinsulin amount were not statistically significant although
there was a trend that Wfs1KO had an increased level of proinsulin. After
incubation in 2 mmol/L glucose solution the proinsulin/insulin ratio in
Wfs1KO was significantly higher than that of WT and Wfs1HZ. RNA-seq
from pancreatic islets found melastatin-related transient receptor potential
subfamily member 5 protein gene (Trpm5) to be downregulated in WFS1-
deficient mice. Functional annotation of RNA sequencing results showed that
WFS1 deficiency influenced significantly the pathways related to tissue mor-
phology, endocrine system development and function, molecular transport
network.
Introduction
Wolfram syndrome (WS, OMIM 222300) is a rare auto-
somal recessive neurodegenerative disorder caused by
mutations in the wolframin gene (WFS1). The main
symptoms of the disease are juvenile-onset diabetes melli-
tus, progressive optic atrophy, diabetes insipidus and
deafness (Barrett and Bundey 1997; Inoue et al. 1998;
Strom et al. 1998). Nonautoimmune degeneration of pan-
creatic b-cells is common for WS patients (Karasik et al.
1989). In patients with WS high levels of endoplasmic
reticulum (ER) stress and pancreatic b-cell death may be
associated with impaired b-cell function as in the case of
type 2 diabetes (T2D) (Fonseca et al. 2005). Genetic stud-
ies have also shown a link between the risk of developing
T2D and WFS1 (Minton et al. 2002; Sandhu et al. 2007;
Florez et al. 2008; Franks et al. 2008; van Hoek et al.
2008; Cheurfa et al. 2011).
WFS1 is a 100 kDa glycoprotein composed of 890
amino acids and has nine transmembrane segments.
Inside the cell WFS1 localizes in the ER (Takeda et al.
2001; Hofmann et al. 2003; Philbrook et al. 2005). Its
location in the ER suggests that WFS1 could participate
in membrane trafficking, processing proteins and/or regu-
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lation of the Ca2+ homeostasis in the ER (Takeda et al.
2001). WFS1 itself may be a Ca2+-channel in the ER or
its regulator (Osman et al. 2003). WFS1 is expressed at
highest levels in brain, heart and pancreatic b-cells (Inoue
et al. 1998; Strom et al. 1998; Hofmann et al. 2003; Ishi-
hara et al. 2004).
Wfs1-mutant mice have been generated in several labo-
ratories (Ishihara et al. 2004; Riggs et al. 2005; Luuk et al.
2008; Koks et al. 2009). One model is a knock-out of the
second exon in [(129Sv 9 B6) 9 B6] F2 background and
the resulting WFS1 protein lacks first 183 amino acids
and NH2-terminus (Ishihara et al. 2004). Riggs et al.
(2005) generated a pancreatic islet specific conditional
Wfs1 mouse model disrupting exon 8. The WFS1-defi-
cient mice (Wfs1tm1Koks) used in current study have also
the exon 8 disrupted resulting in the deletion of amino
acids 360–890 (Luuk et al. 2008; Koks et al. 2009).
Mice with a loss of function of the Wfs1 gene exhibit
b-cell loss, which may result from high levels of ER stress,
cell cycle dysfunction, and apoptosis (Fonseca et al. 2005;
Riggs et al. 2005; Takei et al. 2006; Yamada et al. 2006).
Insulin secretion from isolated islets of mice with a dis-
rupted Wfs1 gene has been shown to be impaired (Ishi-
hara et al. 2004). However, there is no more detailed
analysis of insulin secretion in Wfs1-mutant mice.
RNA-sequencing (RNA-seq) has become a great tool
for transcriptomic studies without the need of previous
knowledge of the targets, allowing identifying novel tran-
scripts and gene expression changes due to some disease
(Mortazavi et al. 2008). There have been studies regarding
pancreatic islets’ transcriptome and differential gene
expression caused by diabetes (Eizirik et al. 2012; Ku
et al. 2012; Moran et al. 2012). However, the transcrip-
tional changes in the islets induced by the deletion of
WFS1 are not known.
The aim of this study was to perform analysis of insu-
lin secretion and proinsulin content in isolated pancreatic
islets of WFS1-deficient mice (Wfs1tm1Koks) (Luuk et al.
2008; Koks et al. 2009). The transcriptome of islets was
analyzed using RNA-seq to describe transcriptional
changes in pancreatic islets associated with Wfs1 defi-
ciency and potentially related to the changes in insulin
secretion.
Methods
Animals
The animal experiments described in this study were per-
formed with permission from Estonian National Board of
Animal Experiments (No. 71, April 8th, 2011) and in
accordance with the European Communities Directive
(86/609/EEC).
Generation of Wfs1 mutant (Wfs1KO, Wfs1tm1Koks) mice
has been described elsewhere (Luuk et al. 2008; Koks et al.
2009). Briefly, most of exon 8 was replaced with a LacZ cas-
sette resulting in the deletion of amino acids 360–890 in
the WFS1 protein. The expressed truncated protein is a
fusion between WFS1 residues 1–359 (N-terminal part)
and LacZ lacking at least seven of the nine transmembrane
domains and the C-terminal portion of endogenous WFS1
protein (Luuk et al. 2008; Koks et al. 2009). In the study 3
genotypes of mice were used: wild-type (WT), heterozy-
gotes for Wfs1 mutation (Wfs1HZ) and homozygotes for
Wfs1 mutation (Wfs1KO). All studies were performed on
male F2 hybrids (129S6/SvEvTac 9 C57BL/6) and mice
were 5–6-month-old at the time of the experiment. Mice
were housed in groups of 6–8 at 20  2°C under 12-h/12-
h light/dark cycle with free access to food and water.
Isolation of pancreatic islets
Pancreatic islets were isolated as previously described
(Shimomura et al. 2009) from six mice in each genotype.
Briefly, mice were executed by cervical dislocation and
the islets isolated by collagenase Type XI digestion
(Sigma-Aldrich, St. Louis, MO, USA, final concentration
1 mg/mL). The inflated pancreas was dissected out and
incubated in a 37°C water bath for 13 min. Only pancre-
ata inflated 100% were used. The tissue was washed twice
with 0.2% BSA (Sigma) and HBSS (Sigma) solution. The
islets were handpicked under stereomicroscope in 0.2%
BSA and HBSS solution. Finally, the islets were picked
into high glucose (4.5 g/L) DMEM/Ham’s F12 media
(PAA/GE Healthcare Life Sciences, Chicago, IL, USA),
containing 10% FBS (Gibco/Thermo Fisher Scientific Inc.,
Waltham, MA, USA), 100 U/mL penicillin and 100 lg/
mL streptomycin (Gibco) and 20 mmol/L L-glutamine
(Invitrogen/Thermo Fisher Scientific Inc., Waltham, MA,
USA). Islets were incubated overnight at 37°C before
insulin secretion assay. During the picking the number of
islets was also counted manually.
Insulin secretion assay
Islets were incubated for 1 h at 37°C and 5% CO2 in 0.2%
BSA and Krebs-Ringer solution (KRBH, 140 mmol/L NaCl,
0.5 mmol/L NaH2PO4, 2 mmol/L NaHCO3, 3.6 mmol/L
KCl, 0.5 mmol/L MgSO4, 2.6 mmol/L CaCl22H2O,
5 mmol/L HEPES, pH 7.4) containing 2 mmol/L glucose.
Then, islets were incubated for 1 h at 37°C and 5% CO2 in
selected assay solution (KRBH and 2 mmol/L, 10 mmol/L
or 20 mmol/L glucose or 200 lmol/L tolbutamide and
2 mmol/L glucose). Tolbutamide (Sigma) was first dis-
solved in 0.2% DMSO (Sigma) with final concentration of
200 lmol/L. Each assay media group contained 5 islets and
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was in duplicate per genotype. After incubation the super-
natant was collected and stored at 20°C until ELISA anal-
ysis. To determine total insulin content, insulin was
extracted from the same islets using 95:5 ethanol:acetic acid
solution (Shimomura et al. 2009).
Insulin concentration was determined with Ultra Sensi-
tive Mouse Insulin ELISA Kit (Crystal Chem Inc., Downers
Grove, IL, USA). Insulin amount was determined sepa-
rately from secretion and islet content samples. To reduce
the effect of variation in islet size on insulin secretion, the
secreted amount of insulin was normalized to the content
of insulin (secreted insulin divided by insulin content).
Proinsulin concentration was measured from islet con-
tent samples with Mouse Proinsulin ELISA Kit (Wuhan
EIAab Science Co., Ltd., Wuhan, China). Proinsulin was
also determined from secretion samples, but the results
were too low and did not reach the detection range. Dif-
ferences in the amount of proinsulin were normalized to
the number of islets used in each well. To compare proin-
sulin/insulin ratio between genotypes the proinsulin con-
centration was divided with corresponding normalized
insulin.
Transcriptome analysis
RNA-sequencing was used for transcriptome analysis. Pan-
creatic islets from 4 animals were used in each genotype
group. Total RNA was isolated from islets using the RNeasy
Mini Kit (Qiagen Inc., Valencia, CA, USA) according to
manufacturer’s protocol and cDNA for sequencing was
synthesized using Ovation RNA-Seq System V2 (NuGEN
Technologies Inc., San Carlos, CA, USA), 10 ng of total
RNA was used. SOLiD DNA Fragment library kit (cDNA
input 2 lg) was used to generate libraries and quality was
controlled with the Agilent Bioanalyzer 2100 (Agilent Tech-
nologies Inc., Santa Clara, CA, USA) before sequencing.
The libraries were marked with different barcodes and
pooled together for the template preparation with auto-
mated SOLiD EZ Bead E80 System and its consumables
(Life Technologies/Thermo Fisher Scientific Inc., Waltham,
MA, USA). The SOLiD 5500xl System and paired end
(75 bp forward and 35 bp reverse) chemistry (Life Tech-
nologies) were used for sequencing. Samples from each ani-
mal were sequenced and analyzed separately.
All the raw sequences are deposited in the sequence
read archive (http://trace.ncbi.nlm.nih.gov/Traces/sra/)
under the accession number GSE65929.
Quantitative real-time PCR validation
The confirmatory quantitative real-time PCR (RT-PCR)
was performed using TaqMan gene expression assays and
chemistry (Life Technologies). Samples were treated with
TURBO DNA-free kit (Ambion/Thermo Fisher Scientific
Inc., Waltham, MA, USA), according to the manufac-
turer’s instructions to remove contaminating genomic
DNA. Total RNA of 10 ng from each sample was sub-
jected to cDNA synthesis using High Capacity cDNA Rev-
erse Transcription Kit (Life Technologies) following the
manufacturer’s protocol. The expression of Glipr2 (glioma
pathogenesis-related protein 2, Mm01341451_m1, FAM),
Trpm5 (Mm01129032_m1, FAM), Gad1 (glutamate decar-
boxylase 1, Mm00725661_s1, FAM), MaoB (monoamine
oxidase B, Mm00555412_m1, FAM), ApoE (apolipopro-
tein E, Mm01307193_g1, FAM) was analyzed using the
ABI Prism 7900 HT Sequence Detection System (Life
Technologies). The same samples were analyzed two
times, but three times for Trpm5.
Statistical analysis
Islet and insulin secretion data are presented as
mean  SEM. Data were analyzed using either one-way or
two-way ANOVA, followed by Tukey post test. A P value of
<0.05 was considered statistically significant (P < 0.05). The
statistical analysis was performed using GraphPad Prism 5
software (GraphPad Software Inc., La Jolla, CA, USA).
Data from RT-PCR are presented as mean of
2DCt  SEM calculated in relation to the TaqMan
Endogenous Control assay for Hprt (hypoxanthine phos-
phoribosyltransferase, Mm00446968_m1, VIC, primer
limited). Data for studied genes were analyzed by one-
way ANOVA and Tukey post hoc test using GraphPad
Prism 5 software (GraphPad Software Inc.) and a P value
<0.05 was considered significant.
For RNA-seq data analysis sequencing reads were
mapped to the mouse genome (version mm10) using the
genomic analysis software LifeScope (Life Technologies).
Data were further analyzed for the differential expression
with the edgeR package implemented in the statistical
software R (http://www.r-project.org/).
Functional annotation of transcriptome
Ingenuity Pathway Analysis (IPA, Ingenuity Systems,
http://www.ingenuity.com) was used to define the func-
tional networks of differentially expressed genes. The
uploaded dataset contained gene identifiers, correspond-
ing false discovery rate (FDR) and fold change values.
As standard workflow in IPA each gene identifier was
mapped to its corresponding gene object in the Ingenuity
Pathways Knowledge Base to generate the list of focus
genes. Based on the connectivity of these focus genes the
IPA software generates networks and calculates a signifi-
cance score for each network. The score is generated from
the P value and is displayed as the negative logarithm of
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that P value. This score indicates the likelihood that the
assembly of a set of focus genes in a network could be
explained by random chance alone. A score of 2 indicates
that there is a 1 in 100 chance that the focus genes are
together in a network due to random chance.
Functional analysis was performed on the entire dataset
and filtered to get only FDR corrected significant genes.
Statistical significance filtering was used to increase the
focus and specificity of analysis.
Results
The number of pancreatic islets
The number of pancreatic islets was manually counted
during handpicking. The difference in number of iso-
lated pancreatic islets between genotypes was statistically
highly significant (WT 303  7.3, Wfs1HZ 176  14
and Wfs1KO 80  7.5, P < 0.001) (Fig. 1). Wfs1KO
animals had remarkably less pancreatic islets than WT
or Wfs1HZ animals indicating a genotypic effect.
Insulin secretion
The basal insulin secretion after incubation in 2 mmol/L
glucose (Fig. 2) for Wfs1KO islets (0.051  0.016) was
reduced compared to WT (0.148  0.014) and Wfs1HZ
(0.143  0.027) islets (P < 0.001).
When islets were stimulated with 10 mmol/L glucose
(Fig. 2) solution, the difference in secreted insulin
between WT (0.201  0.009) and Wfs1KO (0.146 
0.020) was significant (P < 0.05), the difference between
Wfs1HZ (0.212  0.018) and Wfs1KO was highly signifi-
cant (P < 0.01).
However, after stimulation with 20 mmol/L glucose
(Fig. 2) there was no significant difference in stimulation
of insulin secretion between the genotypes (WT
0.220  0.0095, Wfs1HZ 0.209  0.0088 and Wfs1KO
0.191  0.0096, P > 0.05).
The response to the sulfonylurea tolbutamide (Fig. 2)
was also significantly impaired in Wfs1KO islets
(0.092  0.016) compared to WT (0.182  0.009,
P < 0.001) and Wfs1HZ (0.168  0.018, P < 0.01) islets.
The dose-dependent-stimulating effect of glucose is seen
in all the genotypes, although insulin secretion did not sta-
tistically differ after stimulation with 10 mmol/L and
20 mmol/L glucose. The lower normalized insulin amount
seen in Wfs1KO mice was primarily due to decreased
insulin secretion, because the insulin content in pancreatic
islets did not significantly differ between genotypes.
Proinsulin amount and proinsulin/insulin
ratio
The average proinsulin amount per islet (Fig. 3) was not
significantly different between the genotypes (2 mmol/L
glucose: WT 4.636  0.739 pmol/L, Wfs1HZ 5.047 
0.969 pmol/L and Wfs1KO 7.958  1.59 pmol/L; 10
mmol/L glucose: WT 4.296  0.805 pmol/L, Wfs1HZ
4.309  0.558 pmol/L and Wfs1KO 5.489  1.56 pmol/L;
20 mmol/L glucose: WT 4.703  0.864 pmol/L, Wfs1HZ
4.333  0.700 pmol/L and Wfs1KO 6.199  1.53 pmol/L;
tolbutamide: WT 5.120  1.08 pmol/L, Wfs1HZ 4.055 
0.852 pmol/L and Wfs1KO 5.202  0.950 pmol/L;
P > 0.05).
When islets were incubated in 2 mmol/L glucose solu-
tion, there was no significant difference in proinsulin/in-
sulin ratio between WT (0.256  0.065) and Wfs1HZ
(0.632  0.150, P > 0.05). However, the much higher
Wfs1KO proinsulin/insulin ratio (6.345  0.680) was
extremely different from ratios of WT and Wfs1HZ geno-
types (P < 0.001) (Fig. 4A). After treating islets with other
glucose doses (10 mmol/L glucose: WT 0.148  0.023,
Wfs1HZ 0.143  0.025 and Wfs1KO 0.321  0.140;
20 mmol/L glucose: WT 0.165  0.016, Wfs1HZ
0.156  0.008 and Wfs1KO 0.204  0.042) and tolbu-
tamide (WT 0.247  0.072, Wfs1HZ 0.175  0.0174 and
Wfs1KO 0.650  0.235) there were no significant differ-
ence in proinsulin/insulin ratio between the genotypes
(P > 0.05) (Fig. 4B). However, the ratio of proinsulin/in-
sulin was constantly higher in Wfs1KO mice indicating a
larger amount of unprocessed insulin in the islets.
Transcriptome analysis
The number of reads per sample varied from 27 million
to 72 million. The number of transcripts mapped to
WT Wfs1HZ Wfs1KO
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Figure 1. Comparison of the number of isolated pancreatic islets
between genotypes. The difference in the number of isolated
pancreatic islets per pancreas between genotypes was statistically
highly significant (***P < 0.001) by one-way ANOVA. Data plotted
as mean  SEM, n = 6.
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mouse genome was 22613 between Wfs1KO and WT,
22619 between Wfs1KO and Wfs1HZ and 22591
between Wfs1HZ and WT. EdgeR exact test of RNA-seq
data revealed 20 genes with FDR under 0.05
(FDR < 0.05) between Wfs1KO and WT islets
(Table 1A), between Wfs1KO and Wfs1HZ were 13
genes with FDR < 0.05 (Table 1B). With FDR < 0.2
there were additional 29 genes different between
Wfs1KO and WT (data not shown), 7 genes between
Wfs1KO and Wfs1HZ (data not shown) and one gene
between Wfs1HZ and WT (Dpep1, logFC = 3.507,
logCPM = 2.759, P = 7.21E–06, FDR = 0.173). The most
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Figure 2. Insulin secretion from isolated islets. Insulin secretion from isolated islets of WT, Wfs1HZ and Wfs1KO littermates are compared in
response to 2 mmol/L, 10 mmol/L or 20 mmol/L glucose (glc) or 200 lmol/L tolbutamide (Tol) solution and normalized to total insulin content.
Insulin secretion from Wfs1KO islets was decreased after incubation in 2 mmol/L and 10 mmol/L glucose and tolbutamide solution, but not
after stimulation with 20 mmol/L glucose solution. Statistical analysis by two-way ANOVA, where *P < 0.05, **P < 0.01 and ***P < 0.001.
Data plotted as mean  SEM, n = 6.
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Figure 3. Comparison of the average amount of proinsulin per islet between the genotypes. The proinsulin amount per islet was not
significantly different between the genotypes (P > 0.05) after stimulation with 200 lmol/L tolbutamide (Tol) or various glucose (glc) solutions.
Statistical analysis by two-way ANOVA, where *P < 0.05, **P < 0.01 and ***P < 0.001. Data plotted as mean  SEM, n = 6.
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significantly downregulated gene associated with insulin
secretion and diabetes in WFS1-deficient islets following
Wfs1 was melastatin-related transient receptor potential
subfamily member 5 (Trpm5).
Various ER stress markers from RNA-seq (Wfs1KO
islets compared to WT islets) are presented in Table 2.
The FDR and log ratio values of these ER stress markers
were not significant.
Ingenuity functional pathway analysis software was
used for more general functional annotation of the dif-
ferential gene sets. Network analysis of the genes with
lowest P values (filter set to P < 0.05 after FDR correc-
tion) of Wfs1KO compared to WT revealed significant
enrichment of tissue morphology, endocrine system
development and function, molecular transport network
(score 33, Fig. 5). Analysis of Wfs1KO compared to
Wfs1HZ revealed a network associated with
cellular development, cellular growth and proliferation,
hepatic system development and function (score 28,
Fig. 6).
Quantitative real-time PCR confirmation
To determine whether similar changes in gene expres-
sion could be observed with RT-PCR analysis the
expression of Glipr2, Trpm5, Gad1, MaoB, ApoE genes
and the values of three genotypes were compared with
one-way ANOVA followed by Tukey post hoc test
(Fig. 7). ApoE and Glipr2 were upregulated according
to RNA-seq, but RT-PCR did not confirm it statisti-
cally, although there was a trend that ApoE and Glipr2
are upregulated in Wfs1KO islets. The downregulation
of Gad1, MaoB, and Trpm5 was confirmed in Wfs1KO
islets (P < 0.05).
Discussion
Previous studies have shown that WFS1-deficient
(Wfs1tm1Koks) mice have disturbed blood glucose regula-
tion and their plasma insulin level is lower, but plasma
proinsulin level higher (Luuk et al. 2009; Noormets et al.
2011; Terasmaa et al. 2011). In this study, the difference
in transcriptome and insulin secretion from isolated pan-
creatic islets of WFS1-deficient (Wfs1tm1Koks) mice were
studied, also differences in proinsulin levels and proin-
sulin/insulin ratio were detected.
WFS1-deficient mice had considerably fewer pancreatic
islets than heterozygous or wild-type mice during isolation.
This has also been noticed in previous studies (Ishihara
et al. 2004; Riggs et al. 2005). The immunohistochemistry
of the same WFS1-deficient (Wfs1tm1Koks) mouse line has
been done by Terasmaa et al. (2011) showing that the islets
of WFS1-deficient mice also seem to be smaller. b-cells with
defective WFS1 are more prone to ER stress induced apop-
tosis (Ishihara et al. 2004; Philbrook et al. 2005; Riggs et al.
2005; Yamada et al. 2006) which could cause the reduced
number of pancreatic islets in WFS1-deficient mice (Riggs
et al. 2005).
According to current RNA-seq results the down- or
upregulation of various ER stress markers was not statically
significant, although it has been shown that the levels of ER
stress markers from all three UPR pathways are increased
in the absence of WFS1 (Yamada et al. 2006; Fonseca et al.
2010). WFS1 is shown to downregulate ATF6ɑ and its
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Figure 4. Proinsulin to insulin ratio. (A) The higher Wfs1KO proinsulin/insulin ratio was significantly different from WT and Wfs1HZ
(***P < 0.001) at 2 mmol/L glucose (glc). (B) The differences between the genotypes in proinsulin/insulin ratio at higher glucose and
tolbutamide (Tol) solutions was not significant (P > 0.05). Statistical analysis by two-way ANOVA, where *P < 0.05, **P < 0.01 and
***P < 0.001. Data plotted as mean  SEM, n = 6.
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Table 1. RNA-seq results of pancreatic islets showing genes with FDR < 0.05.
Gene Log ratio P value
False discovery
rate (q-value) Entrez gene name
(A). Wfs1KO compared to WT
Wfs1 2.663 2.18E–12 5.24E–08 Wolfram syndrome 1 (wolframin)
Glipr2 3.139 1.42E–09 1.71E–05 GLI pathogenesis-related 2
Trpm5 2.422 4.05E–09 3.25E–05 Transient receptor potential cation channel, subfamily M, member 5
Gad1 2.671 9.94E–08 5.98E–04 Glutamate decarboxylase 1 (brain, 67 kDa)
Spock1 1.801 8.71E–07 4.19E–03 Sparc/osteonectin, cwcv and kazal-like domains proteoglycan (testican) 1
Sprr1a 2.623 1.36E–06 5.44E–03 Small proline-rich protein 1A
Bcat1 1.821 1.67E–06 5.75E–03 Branched chain amino-acid transaminase 1, cytosolic
Csf3 2.332 2.03E–06 6.12E–03 Colony-stimulating factor 3 (granulocyte)
Nrxn1 1.404 5.14E–06 1.38E–02 Neurexin 1
Prss23 1.769 7.19E–06 1.62E–02 Protease, serine, 23
Aw551984 1.551 7.40E–06 1.62E–02 Expressed sequence AW551984
Cxcl9 3.394 8.28E–06 1.66E–02 Chemokine (C-X-C motif) ligand 9
MaoB 1.86 1.02E–05 1.89E–02 Monoamine oxidase B
Kcns3 4.122 1.17E–05 2.02E–02 Potassium voltage-gated channel, delayed-rectifier, subfamily S, member 3
Zfp36 1.709 1.71E–05 2.74E–02 ZFP36 ring finger protein
Egr1 1.392 2.65E–05 3.97E–02 Early growth response 1
ApoE 1.712 2.91E–05 3.97E–02 Apolipoprotein E
Itgb3 1.701 2.97E–05 3.97E–02 Integrin, beta 3 (platelet glycoprotein IIIa, antigen CD61)
Ccdc85B 1.566 3.38E–05 4.07E–02 Coiled-coil domain containing 85B
Cnnm1 1.767 3.38E–05 4.07E–02 Cyclin M1
(B). Wfs1KO compared to Wfs1HZ
Trpm5 3.292 2.04E–12 4.92E–08 Transient receptor potential cation channel, subfamily M, member 5
Gad1 2.834 6.40E–08 7.70E–04 Glutamate decarboxylase 1 (brain, 67kDa)
Bcat1 1.871 4.53E–07 2.82E–03 Branched chain amino-acid transaminase 1, cytosolic
Serpina7 2.855 4.68E–07 2.82E–03 Serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 7
Dpyd 1.746 2.34E–06 9.38E–03 Dihydropyrimidine dehydrogenase
Spock1 1.758 3.01E–06 1.01E–02 Sparc/osteonectin, cwcv and kazal-like domains proteoglycan (testican) 1
Npas4 3.008 3.35E–06 1.01E–02 Neuronal PAS domain protein 4
Cxcl9 3.563 4.36E–06 1.14E–02 Chemokine (C-X-C motif) ligand 9
Sprr1a 2.328 4.73E–06 1.14E–02 Small proline-rich protein 1A
Insrr 2.356 7.32E–06 1.49E–02 Insulin receptor-related receptor
Cpb2 2.129 7.44E–06 1.49E–02 Carboxypeptidase B2 (plasma)
Bhlha15 1.759 2.38E–05 4.40E–02 Basic helix-loop-helix family, member a15
FDR, false discovery rate; Wfs1HZ, pancreatic islets of Wfs1 heterozygous mice; Wfs1KO; pancreatic islets of Wfs1 deficient mice.
Table 2. RNA-seq results of ER stress markers (Wfs1KO compared to WT islets).
Gene Log ratio P value
False discovery
rate (q-value) Entrez gene name
Atf6 0.535 0.095 1 Activating transcription factor 6
Ern1 (Ire1a) 0.211 0.795 1 Endoplasmic reticulum to nucleus signaling 1 (inositol-requiring enzyme 1)
Xbp1 0.017 0.697 1 X-box-binding protein 1
Eif2ak3 (Perk) 0.214 0.409 1 Eukaryotic translation initiation factor 2 a kinase 3
(protein kinase R-like endoplasmic reticulum kinase)
Atf4 0.193 0.633 1 Activating transcription factor 4
Ddit3 (Chop) 0.215 0.595 1 DNA-damage inducible transcript 3 (C/EBP homologous protein)
Hspa5 (Bip) 0.347 0.176 1 Heat-shock 70 kDa protein 5 (glucose-regulated protein, 78 kDa)
ER, endoplasmic reticulum; WT, wild-type.
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downstream targets (Fonseca et al. 2010). It has been
shown that in the pancreatic b-cells of WFS1-deficient mice
the expression of GRP78 and GRP94 has increased, also
levels of spliced XPB1 (Yamada et al. 2006). The possible
explanation may be that gene expression might not always
correspond to protein level and most of the ER stress
marker studies have been done in cell lines and also the
mouse line (Wfs1tm1Koks) used in this study that is not a
complete knock-out of Wfs1. A truncated WFS1 protein
lacking amino acids 360–890 (C-terminal portion) and at
least seven of the nine transmembrane domains is
expressed resulting in defective function (Luuk et al. 2008;
Koks et al. 2009).
WFS1-deficient pancreatic islets secreted less insulin
after incubation in 2 mmol/L and 10 mmol/L glucose
solution compared to WT and Wfs1HZ islets. Surpris-
ingly the overall secretion after stimulation was not as
high as expected and there was no statistically significant
difference after stimulation with 20 mmol/L glucose,
however, there was a trend that Wfs1KO islets secreted
less insulin. The rise of insulin secreted after stimulation
with 10 mmol/L compared to 20 mmol/L glucose was
greater for Wfs1KO islets while the amount of secreted
insulin stayed more or less at the same level for WT and
Wfs1HZ islets, which was not expected and could not be
explained. In general this result is in accordance with pre-
vious studies made by Ishihara et al. (2004) and Riggs
et al. (2005), although Ishihara et al. (2004) could not see
a difference in insulin secretion after incubation in
2.5 mmol/L glucose (Ishihara et al. 2004; Riggs et al.
2005). This variation could be due to differences in Wfs1
mouse models as current WFS1-deficient mice have a dis-
rupted exon 8 (Koks et al. 2009) and the other model is
a complete knock-out of exon 2 (Ishihara et al. 2004).
The disruption of exon 8 leads to a dysfunctional protein
mimicking more accurately Wolfram syndrome as most
mutations in the WFS1 gene occur in exon 8 (Cryns et al.
2003). Wfs1KO islets also showed a significant reduction
in the amount of insulin secreted in response to sulfony-
lurea tolbutamide. Tolbutamide forces b-cells to secrete
insulin independent of glucose metabolism by closing the
ATP-sensitive K+ (KATP) channels directly which results
Figure 5. Associated functional network of Wfs1KO compared to WT. Functional annotation revealed that genes with highest expressional
changes because of WFS1 deficiency belong to the “tissue morphology, endocrine system development and function, molecular transport”
functional network. Red symbols are upregulated genes, green symbols are downregulated genes, and the numbers reflect the t-value of the
statistical comparison with Bayesian moderated t-test.
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in membrane depolarization, Ca2+ influx and insulin
release (Ashcroft and Rorsman 1989). WFS1 may there-
fore exert its effect on insulin secretion at or downstream
of the KATP channel.
In vivo studies with WFS1-deficient mice have shown
that Wfs1KO mice have lower plasma insulin level than
WT mice (Noormets et al. 2011; Terasmaa et al. 2011).
In this study, there was no difference in insulin secretion
between WT and Wfs1HZ, which is in accordance with
in vivo results by Terasmaa et al. (2011). The lower insu-
lin amount seen in Wfs1KO mice was primarily due to
decreased insulin secretion, because the insulin content in
pancreatic islets did not significantly differ between geno-
types. These and previous results indicate a defect in insu-
lin secretion in WFS1-deficient pancreatic b-cells
(Ishihara et al. 2004; Hatanaka et al. 2011).
Hatanaka et al. (2011) showed that WFS1 localized in
b-cells and also to secretory granules and WFS1 deficiency
caused changes in the intragranular pH, which in turn
caused defects in proinsulin processing. Therefore, the
level of circulating proinsulin is higher in WFS1-deficient
mice (Noormets et al. 2011). In this study, there were no
significant differences in proinsulin amount per pancre-
atic islet between genotypes, although there was a trend
that Wfs1KO had an increased level of proinsulin. The
Wfs1KO proinsulin/insulin ratio was significantly higher
compared to WT and Wfs1HZ only after incubation in
2 mmol/L glucose solution. There was also a trend that
Wfs1KO proinsulin/insulin ratio was increased after stim-
ulation with other solutions. Higher proinsulin/insulin
ratio is associated with T2D (Mykkanen et al. 1997) indi-
cating that WFS1-deficient mice have a diabetic pheno-
type. The current results also indicate that there may be a
problem with conversion of proinsulin to insulin and
release of insulin from granules. This is in accordance
with previous studies by Hatanaka et al. (2011).
According to functional annotation of RNA-seq results
genes with highest expressional changes due to WFS1
deficiency belong to the “tissue morphology, endocrine
system development and function, molecular transport”
Figure 6. Associated functional network of Wfs1KO compared to Wfs1HZ. Functional annotation revealed that differences in genes with
highest expressional changes belong to the “cellular development, cellular growth and proliferation, hepatic system development and function”
functional network. Red symbols are upregulated genes, green symbols are downregulated genes, and the numbers reflect the t-value of the
statistical comparison with Bayesian moderated t-test.
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functional network. Although only four samples of each
genotype were sequenced, RNA sequencing revealed that
melastatin-related transient receptor potential subfamily
member 5 (Trpm5) is downregulated in that pathway of
Wfs1KO pancreatic islets. TRPM5 (melastatin-related
transient receptor potential subfamily member 5 protein)
is expressed in the pancreatic islets of Langerhans and
regulates Ca2+ oscillations contributing to insulin secre-
tion (Brixel et al. 2010; Colsoul et al. 2010). Colsoul et al.
(2010) showed that the action potentials of Trpm5-
mutant islet cells did not change, but the frequency of
oscillations did. Trpm5-mutant islet cells maintain slow
oscillations but lack of fast oscillations (Colsoul et al.
2010).
TRPM5 is shown to regulate glucose-stimulated insulin
secretion as Trpm5 knock-out mice have impaired glucose
Figure 7. Results of validating RT-PCR. ApoE and Glipr2 were upregulated according to RNA-seq, but RT-PCR did not confirm it statistically,
although there was a trend that ApoE and Glipr2 are upregulated in Wfs1KO islets. The downregulation of Gad1, MaoB, and Trpm5 was
confirmed in Wfs1KO islets. Statistical analysis by one-way ANOVA followed by Tukey post hoc test, where *P < 0.05, **P < 0.01 and
***P < 0.001. Data plotted as mean  SEM, n = 4.
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tolerance. They have prolonged elevation of blood glucose
levels, suggesting disturbances in insulin secretion (Brixel
et al. 2010; Colsoul et al. 2010). TRPM5 forms a func-
tional calcium-activated nonselective cation channel con-
ducting mainly Na+ and K+ ions without significant
permeation to Ca2+. Its activation presumably causes
membrane depolarization downstream of the closure of
KATP channels (Prawitt et al. 2003; Brixel et al. 2010),
what may be an important step leading to activation of
voltage-dependent calcium channels in glucose stimulated
insulin secretion (Henquin et al. 2009; Brixel et al. 2010).
Brixel et al. (2010) hypothesize that TRPM5 may also
have an additional role in the vesicle–membrane fusion
process as Trpm5-mutant islets had still decreased insulin
secretion when stimulated with arginine (Brixel et al.
2010). Although the exact mechanisms how TRPM5
activity is regulated and how it combines different types
of sensory input in different cells are not known, the pro-
posed hypothesis would help to explain how TRPM5 and
WFS1 might interact or influence each other. The func-
tional annotation of RNA-seq results also showed that
WFS1 and TRPM5 might be connected over proinsulin
processing and/or Ca2+ signaling as it has been reported
that the islets of Wfs1 knock-out mice have impaired
Ca2+ signaling (Ishihara et al. 2004).
Further studies are needed to verify the functional
interaction between WFS1 and TRPM5 in the regulation
of insulin secretion and how this downregulation may
contribute to diabetes-like phenotype of WFS1-deficient
mice. Although this study has some limitations, mainly
regarding islet stimulation induction and sample size, in
conclusion, mice with disrupted Wfs1 gene had fewer
pancreatic islets and defective insulin secretion explaining
their diabetes-like phenotype. RNA-sequencing of pancre-
atic islets showed that interestingly Trpm5 is downregu-
lated in WFS1-deficient islets and the pathways related to
tissue morphology, endocrine system development and
function, molecular transport network are influenced.
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